VanEck Biotech ETF (BBH)
Assets | $435.18M |
Expense Ratio | 0.35% |
PE Ratio | 16.61 |
Shares Out | 2.65M |
Dividend (ttm) | $0.71 |
Dividend Yield | 0.43% |
Ex-Dividend Date | Dec 18, 2023 |
Payout Ratio | 7.22% |
1-Year Return | +2.78% |
Volume | 2,206 |
Open | 164.23 |
Previous Close | 164.06 |
Day's Range | 164.23 - 165.75 |
52-Week Low | 142.51 |
52-Week High | 171.05 |
Beta | 0.84 |
Holdings | 26 |
Inception Date | Dec 20, 2011 |
About BBH
Fund Home PageThe VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.
Top 10 Holdings
68.64% of assetsName | Symbol | Weight |
---|---|---|
Amgen Inc. | AMGN | 16.48% |
Vertex Pharmaceuticals Incorporated | VRTX | 9.53% |
Regeneron Pharmaceuticals, Inc. | REGN | 7.87% |
Gilead Sciences, Inc. | GILD | 7.19% |
Moderna, Inc. | MRNA | 6.24% |
Biogen Inc. | BIIB | 4.60% |
IQVIA Holdings Inc. | IQV | 4.52% |
argenx SE | ARGX | 4.34% |
ICON PLC | ICLR | 4.22% |
Illumina, Inc. | ILMN | 3.66% |
Dividends
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 18, 2023 | $0.7127 | Dec 22, 2023 |
Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
Dec 20, 2018 | $0.551 | Dec 27, 2018 |
News
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
A Divergence Has Occurred In Healthcare
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.